cc1c7e4b-89a0-4d94-b9e5-293c2eacadd9
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.500
- MYC_TARGETS_V2+0.400
- ADIPOGENESIS+0.300
- DNA_REPAIR+0.200
- FATTY_ACID_METABOLISM+0.200
- PANCREAS_BETA_CELLS+0.200
- SPERMATOGENESIS+0.200
- WNT_BETA_CATENIN_SIGNALING+0.200
- CHOLESTEROL_HOMEOSTASIS+0.100
- E2F_TARGETS+0.100
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.600
- INFLAMMATORY_RESPONSE-0.600
- INTERFERON_ALPHA_RESPONSE-0.600
- INTERFERON_GAMMA_RESPONSE-0.600
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.500
- IL6_JAK_STAT3_SIGNALING-0.500
- KRAS_SIGNALING_UP-0.500
- ANDROGEN_RESPONSE-0.400
- ANGIOGENESIS-0.400
- COMPLEMENT-0.400
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR25043617 | — | — | 0.906 |
| 2 | TCGA-CV-6962-01A-11R-1915-07 | — | — | 0.888 |
| 3 | a9e8b311-dfde-4c34-80a2-5e64f94c596b | — | — | 0.887 |
| 4 | 63e18642-fcf3-460b-95de-de16428dea6d | — | — | 0.887 |
| 5 | 20110070.TNBC | — | E | 0.878 |
| 6 | 85d43afd-9aac-48ca-a9c4-00357b7207e1 | — | — | 0.876 |
| 7 | SRR2669446 | — | — | 0.875 |
| 8 | TCGA-B6-A0IB-01A-11R-A034-07 | — | B | 0.874 |
| 9 | SJEPD001539_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.867 |
| 10 | TCGA-CQ-6225-01A-11R-1915-07 | — | — | 0.862 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.500 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.400 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.300 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.200 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.200 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.200 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.200 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.100 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.100 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.100 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.100 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.100 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.100 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.100 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.100 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.100 | Idelalisib | — uncovered |